Cancer Immunology, Immunotherapy View Homepage


Ontology type: schema:Periodical     


Journal Info

START YEAR

1982

PUBLISHER

Springer Berlin Heidelberg

LANGUAGE

en

HOMEPAGE

http://link.springer.com/journal/262

Recent publications latest 20 shown

  • 2019-04-10 Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma.
  • 2019-04-08 Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy.
  • 2019-04-06 T-cell recognition of non-mutated tumor antigens in healthy individuals: connecting endogenous immunity and tumor dormancy.
  • 2019-04-06 Sirtuin2 enhances the tumoricidal function of liver natural killer cells in a mouse hepatocellular carcinoma model.
  • 2019-04-05 Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
  • 2019-04-05 Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy.
  • 2019-04-05 Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.
  • 2019-04-04 "Tumor Immunology Meets Oncology (TIMO) XIV", May 24-26th 2018, Halle/Saale, Germany.
  • 2019-04-03 Unlocking the therapeutic potential of primary tumor-draining lymph nodes.
  • 2019-04 Acknowledgements
  • 2019-04 Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma
  • 2019-04 Interactions among myeloid regulatory cells in cancer
  • 2019-04 Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice
  • 2019-04 MDSCs in infectious diseases: regulation, roles, and readjustment
  • 2019-04 MDSC and beyond: a symposium-in-writing on myeloid cells with immunoregulatory activity by members of the Mye-EUNITER network
  • 2019-04 Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates
  • 2019-04 The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma
  • 2019-04 Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics
  • 2019-04 Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation
  • 2019-04 A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33160", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Oncology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B14000", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B11001", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Cancer Research", 
            "type": "DefinedTerm"
          }
        ], 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "0.99", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "1.899", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2017", 
            "ratingValue": "4.225", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2016", 
            "ratingValue": "4.711", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2016", 
            "ratingValue": "4.711", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2015", 
            "ratingValue": "4.846", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2015", 
            "ratingValue": "4.846", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2014", 
            "ratingValue": "3.941", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2014", 
            "ratingValue": "3.941", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2013", 
            "ratingValue": "3.943", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2013", 
            "ratingValue": "3.943", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2010", 
            "ratingValue": "4.293", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2010", 
            "ratingValue": "4.293", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2009", 
            "ratingValue": "3.791", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2009", 
            "ratingValue": "3.791", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2012", 
            "ratingValue": "3.637", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2012", 
            "ratingValue": "3.637", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2011", 
            "ratingValue": "3.701", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2011", 
            "ratingValue": "3.701", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2008", 
            "ratingValue": "3.804", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2008", 
            "ratingValue": "3.804", 
            "type": "Rating"
          }
        ], 
        "description": "

    Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology.\u00a0 The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others\u2019 results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms.

    In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:

    • \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u201cFocussed Research Reviews,\u201d published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.
    • \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u201cSymposia-in-Writing,\u201d which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.

    CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and\u00a0Sociedad Espa\u00f1ola de Inmunologia-Grupo Espa\u00f1ola de\u00a0InmunoTerapia\u00a0(SEI-GEIT).

    CIMT: http://www.cimt.eu/home

    CCIC: http://www.immunotherapycancer.ca/

    JACI: http://www.jaci.jp/eng/index.html

    NIBIT: http://www.nibit.org/index.php

    SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&Upfqym5uom=GK\u00a0\u00a0

    CITIM: http://www.canceritim.org", "editor": [ { "familyName": "Pawelec", "givenName": "Graham", "type": "Person" } ], "id": "sg:journal.1096240", "inLanguage": [ "en" ], "isAccessibleForFree": false, "issn": [ "0340-7004", "1432-0851" ], "license": "Hybrid (Open Choice)", "name": "Cancer Immunology, Immunotherapy", "productId": [ { "name": "scopus_id", "type": "PropertyValue", "value": [ "29152" ] }, { "name": "wos_id", "type": "PropertyValue", "value": [ "0340-7004/CANCER IMMUNOLOGY IMMUNOTHERAPY" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "8605732" ] }, { "name": "nsd_ids_id", "type": "PropertyValue", "value": [ "339854" ] }, { "name": "springer_id", "type": "PropertyValue", "value": [ "262" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "sn 84010370" ] }, { "name": "dimensions_id", "type": "PropertyValue", "value": [ "96240" ] }, { "name": "era_ids_id", "type": "PropertyValue", "value": [ "15463" ] } ], "publisher": { "name": "Springer Berlin Heidelberg", "type": "Organization" }, "publisherImprint": "Springer", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1096240" ], "sdDataset": "journals", "sdDatePublished": "2019-03-18T11:05", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "file:///home/ubuntu/piotr/scigraph_export/journals_20190313_sn_only.jsonl", "startYear": "1982", "type": "Periodical", "url": "http://link.springer.com/journal/262" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1096240'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1096240'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1096240'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1096240'


     

    This table displays all metadata directly associated to this object as RDF triples.

    217 TRIPLES      21 PREDICATES      52 URIs      45 LITERALS      32 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1096240 schema:about sg:ontologies/product-market-codes/B11001
    2 sg:ontologies/product-market-codes/B14000
    3 sg:ontologies/product-market-codes/H33160
    4 schema:contentRating N019f688f873e40d7b8149fe4af1fb80f
    5 N09e729bcebbb4484a6763b93ddc35d8d
    6 N0af067057ef54515ac7f25a186cdd7c2
    7 N20326e5ab1704ae0b75cb075ed341cf7
    8 N255745e0b5424510878e8703b42bf7dc
    9 N3134d5b8836a4afaaa1df62bff9a5ee4
    10 N3409853c9fe041ce96c3c06957ea6857
    11 N4ca4d5941508426480116ff48d4a8a1d
    12 N5223add479884d7687e9114cffb06de4
    13 N6a01634854f34f9bb499df4eac0936a4
    14 N836092eafbfa4c8394b0f941f7d92e4c
    15 N840fac3d6a2741579c22ee236b133d51
    16 N8a7062fc80c04027a5379c8774f26655
    17 N8d9ea0ae34c541d18cc39c9974e2c980
    18 N918a7eb0b4b84c7cbb0aea211827a293
    19 N9c7adb1c29784648932ca34b287b373d
    20 Naa8a3c8312a54533a579633cd6489506
    21 Nab5f49872cdc48388dbd8da079aa192d
    22 Nb3d3c139b0a24293b6e7789935910538
    23 Nd37da3ec5e1b4ca38b38906d52d10491
    24 Nfd551c2f5813485abad7c6dcb1cb7244
    25 schema:description <p>Since its inception in 1976, <i>Cancer Immunology, Immunotherapy</i> (CII) has reported significant advances in the field of tumor immunology.  The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms. </p><p>In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:</p><ul><li>         “Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.</li><li>        “Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.</li></ul><p>CII is affiliated with the <i>Association for Cancer Immunotherapy (CIMT)</i>,<i> Canadian Cancer Immunotherapy Consortium (CCIC)</i>, <i>The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT</i>),<i> </i>and <i>Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT)</i>.</p><p>CIMT: http://www.cimt.eu/home</p><p>CCIC: http://www.immunotherapycancer.ca/</p><p>JACI: http://www.jaci.jp/eng/index.html</p><p>NIBIT: http://www.nibit.org/index.php</p><p>SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&amp;Upfqym5uom=GK  </p>CITIM: http://www.canceritim.org
    26 schema:editor N2bc0cdea96fc472c811070a7f649d323
    27 schema:inLanguage en
    28 schema:isAccessibleForFree false
    29 schema:issn 0340-7004
    30 1432-0851
    31 schema:license Hybrid (Open Choice)
    32 schema:name Cancer Immunology, Immunotherapy
    33 schema:productId N0d4e30e3fa6e4ead90a630b5f9a7bfe6
    34 N59ee1e4171f345028935cb04f9dc2d98
    35 N61d05419b910497ea98339cbb6563c94
    36 N9035cdaf444e44e2bd556ecfb127fc1a
    37 N90eb77d02dd74d3b997aab3f5dd8780e
    38 Nbf9596351d6d466185ace04dcadb6500
    39 Ncd1b1c5c7fd64f71b7f5d680acc9e514
    40 Nceb8b3e6c314416f9221225aa915a924
    41 schema:publisher N5773bbcf879f474e8500edf89ca396e8
    42 schema:publisherImprint Springer
    43 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1096240
    44 schema:sdDatePublished 2019-03-18T11:05
    45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    46 schema:sdPublisher N3913f1ef290f4a3bbeee4b847128b9dc
    47 schema:startYear 1982
    48 schema:url http://link.springer.com/journal/262
    49 sgo:license sg:explorer/license/
    50 sgo:sdDataset journals
    51 rdf:type schema:Periodical
    52 N019f688f873e40d7b8149fe4af1fb80f schema:author Ne7d205d796de4196a8dbf85a3072c21e
    53 schema:dateCreated 2011
    54 schema:ratingValue 3.701
    55 rdf:type schema:Rating
    56 N09e729bcebbb4484a6763b93ddc35d8d schema:author Nb9dfa2c6d7a44d308155ff30dc017794
    57 schema:ratingValue 1.899
    58 rdf:type schema:Rating
    59 N0af067057ef54515ac7f25a186cdd7c2 schema:author N603dbf37d5924cc6b0309d13ef00fe05
    60 schema:dateCreated 2012
    61 schema:ratingValue 3.637
    62 rdf:type schema:Rating
    63 N0d4e30e3fa6e4ead90a630b5f9a7bfe6 schema:name nsd_ids_id
    64 schema:value 339854
    65 rdf:type schema:PropertyValue
    66 N13a8880f370d4ee2a9dc3687b20d740c rdf:first impact_factor_wos
    67 rdf:rest rdf:nil
    68 N1434df90613045c79956b0eb07a14948 rdf:first impact_factor_wos
    69 rdf:rest rdf:nil
    70 N17d0900b3724419abfb6f7481467942c rdf:first impact_factor_wos
    71 rdf:rest rdf:nil
    72 N192e98c493114a1bb8409b342abfcc7e rdf:first snip
    73 rdf:rest rdf:nil
    74 N1fba4e957458410b85900fd78a4acc5f rdf:first impact_factor_wos
    75 rdf:rest rdf:nil
    76 N20326e5ab1704ae0b75cb075ed341cf7 schema:author N1434df90613045c79956b0eb07a14948
    77 schema:dateCreated 2010
    78 schema:ratingValue 4.293
    79 rdf:type schema:Rating
    80 N255745e0b5424510878e8703b42bf7dc schema:author N7fb5fb4694204ddc85e3d3f61c588e6d
    81 schema:dateCreated 2011
    82 schema:ratingValue 3.701
    83 rdf:type schema:Rating
    84 N2bc0cdea96fc472c811070a7f649d323 rdf:first Nf79b31485e1846dc957b44c2aa608680
    85 rdf:rest rdf:nil
    86 N30d1925f907c4eabbd72f9a42ea97b6f rdf:first impact_factor_wos
    87 rdf:rest rdf:nil
    88 N3134d5b8836a4afaaa1df62bff9a5ee4 schema:author N87059ea7256c48069a64932be66ec658
    89 schema:dateCreated 2014
    90 schema:ratingValue 3.941
    91 rdf:type schema:Rating
    92 N33191d1aa900482b9d373f4b6ed72e36 rdf:first impact_factor_wos
    93 rdf:rest rdf:nil
    94 N3409853c9fe041ce96c3c06957ea6857 schema:author N4a9e7df139194d5488bc7b96faf1907d
    95 schema:dateCreated 2017
    96 schema:ratingValue 4.225
    97 rdf:type schema:Rating
    98 N3913f1ef290f4a3bbeee4b847128b9dc schema:name Springer Nature - SN SciGraph project
    99 rdf:type schema:Organization
    100 N4a9e7df139194d5488bc7b96faf1907d rdf:first impact_factor_wos
    101 rdf:rest rdf:nil
    102 N4ca4d5941508426480116ff48d4a8a1d schema:author Nbb337e2970f447d6b6bce5292438cb92
    103 schema:dateCreated 2010
    104 schema:ratingValue 4.293
    105 rdf:type schema:Rating
    106 N5223add479884d7687e9114cffb06de4 schema:author Ne4616f385a3242aba745815a3ad09b4b
    107 schema:dateCreated 2015
    108 schema:ratingValue 4.846
    109 rdf:type schema:Rating
    110 N5773bbcf879f474e8500edf89ca396e8 schema:name Springer Berlin Heidelberg
    111 rdf:type schema:Organization
    112 N59ee1e4171f345028935cb04f9dc2d98 schema:name springer_id
    113 schema:value 262
    114 rdf:type schema:PropertyValue
    115 N5f4e02f5dfca4f539aa65c1629b70c31 rdf:first impact_factor_wos
    116 rdf:rest rdf:nil
    117 N603dbf37d5924cc6b0309d13ef00fe05 rdf:first impact_factor_wos
    118 rdf:rest rdf:nil
    119 N61d05419b910497ea98339cbb6563c94 schema:name era_ids_id
    120 schema:value 15463
    121 rdf:type schema:PropertyValue
    122 N6a01634854f34f9bb499df4eac0936a4 schema:author Nce4a52c3b46c415aad22143ad690a77b
    123 schema:dateCreated 2009
    124 schema:ratingValue 3.791
    125 rdf:type schema:Rating
    126 N7fb5fb4694204ddc85e3d3f61c588e6d rdf:first impact_factor_wos
    127 rdf:rest rdf:nil
    128 N836092eafbfa4c8394b0f941f7d92e4c schema:author N13a8880f370d4ee2a9dc3687b20d740c
    129 schema:dateCreated 2013
    130 schema:ratingValue 3.943
    131 rdf:type schema:Rating
    132 N840fac3d6a2741579c22ee236b133d51 schema:author N192e98c493114a1bb8409b342abfcc7e
    133 schema:ratingValue 0.99
    134 rdf:type schema:Rating
    135 N87059ea7256c48069a64932be66ec658 rdf:first impact_factor_wos
    136 rdf:rest rdf:nil
    137 N8a7062fc80c04027a5379c8774f26655 schema:author N33191d1aa900482b9d373f4b6ed72e36
    138 schema:dateCreated 2009
    139 schema:ratingValue 3.791
    140 rdf:type schema:Rating
    141 N8d9ea0ae34c541d18cc39c9974e2c980 schema:author N5f4e02f5dfca4f539aa65c1629b70c31
    142 schema:dateCreated 2016
    143 schema:ratingValue 4.711
    144 rdf:type schema:Rating
    145 N9035cdaf444e44e2bd556ecfb127fc1a schema:name nlm_unique_id
    146 schema:value 8605732
    147 rdf:type schema:PropertyValue
    148 N90eb77d02dd74d3b997aab3f5dd8780e schema:name lccn_id
    149 schema:value sn 84010370
    150 rdf:type schema:PropertyValue
    151 N918a7eb0b4b84c7cbb0aea211827a293 schema:author Nf034b84fe97f4b9e8fe84c327b2d74ac
    152 schema:dateCreated 2015
    153 schema:ratingValue 4.846
    154 rdf:type schema:Rating
    155 N9af9f0b9c8ad4197b09bf8b5dbae0f1d rdf:first impact_factor_wos
    156 rdf:rest rdf:nil
    157 N9c7adb1c29784648932ca34b287b373d schema:author Ne924e9e67adc49b89ffc7b9c4a21cfbd
    158 schema:dateCreated 2013
    159 schema:ratingValue 3.943
    160 rdf:type schema:Rating
    161 Naa8a3c8312a54533a579633cd6489506 schema:author N1fba4e957458410b85900fd78a4acc5f
    162 schema:dateCreated 2008
    163 schema:ratingValue 3.804
    164 rdf:type schema:Rating
    165 Nab5f49872cdc48388dbd8da079aa192d schema:author Nd7d69f9d796a41e392442a56814c75c8
    166 schema:dateCreated 2008
    167 schema:ratingValue 3.804
    168 rdf:type schema:Rating
    169 Nb3d3c139b0a24293b6e7789935910538 schema:author N30d1925f907c4eabbd72f9a42ea97b6f
    170 schema:dateCreated 2014
    171 schema:ratingValue 3.941
    172 rdf:type schema:Rating
    173 Nb9dfa2c6d7a44d308155ff30dc017794 rdf:first sjr
    174 rdf:rest rdf:nil
    175 Nbb337e2970f447d6b6bce5292438cb92 rdf:first impact_factor_wos
    176 rdf:rest rdf:nil
    177 Nbf9596351d6d466185ace04dcadb6500 schema:name wos_id
    178 schema:value 0340-7004/CANCER IMMUNOLOGY IMMUNOTHERAPY
    179 rdf:type schema:PropertyValue
    180 Ncd1b1c5c7fd64f71b7f5d680acc9e514 schema:name dimensions_id
    181 schema:value 96240
    182 rdf:type schema:PropertyValue
    183 Nce4a52c3b46c415aad22143ad690a77b rdf:first impact_factor_wos
    184 rdf:rest rdf:nil
    185 Nceb8b3e6c314416f9221225aa915a924 schema:name scopus_id
    186 schema:value 29152
    187 rdf:type schema:PropertyValue
    188 Nd37da3ec5e1b4ca38b38906d52d10491 schema:author N17d0900b3724419abfb6f7481467942c
    189 schema:dateCreated 2016
    190 schema:ratingValue 4.711
    191 rdf:type schema:Rating
    192 Nd7d69f9d796a41e392442a56814c75c8 rdf:first impact_factor_wos
    193 rdf:rest rdf:nil
    194 Ne4616f385a3242aba745815a3ad09b4b rdf:first impact_factor_wos
    195 rdf:rest rdf:nil
    196 Ne7d205d796de4196a8dbf85a3072c21e rdf:first impact_factor_wos
    197 rdf:rest rdf:nil
    198 Ne924e9e67adc49b89ffc7b9c4a21cfbd rdf:first impact_factor_wos
    199 rdf:rest rdf:nil
    200 Nf034b84fe97f4b9e8fe84c327b2d74ac rdf:first impact_factor_wos
    201 rdf:rest rdf:nil
    202 Nf79b31485e1846dc957b44c2aa608680 schema:familyName Pawelec
    203 schema:givenName Graham
    204 rdf:type schema:Person
    205 Nfd551c2f5813485abad7c6dcb1cb7244 schema:author N9af9f0b9c8ad4197b09bf8b5dbae0f1d
    206 schema:dateCreated 2012
    207 schema:ratingValue 3.637
    208 rdf:type schema:Rating
    209 sg:ontologies/product-market-codes/B11001 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    210 schema:name Cancer Research
    211 rdf:type schema:DefinedTerm
    212 sg:ontologies/product-market-codes/B14000 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    213 schema:name Immunology
    214 rdf:type schema:DefinedTerm
    215 sg:ontologies/product-market-codes/H33160 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    216 schema:name Oncology
    217 rdf:type schema:DefinedTerm
     




    Preview window. Press ESC to close (or click here)


    ...